FSPHX
Price
$23.88
Change
-$0.44 (-1.81%)
Updated
Jun 2 closing price
Net Assets
5.78B
HGHRX
Price
$37.40
Change
-$0.59 (-1.55%)
Updated
Jun 2 closing price
Net Assets
722.86M
Interact to see
Advertisement

FSPHX vs HGHRX

Header iconFSPHX vs HGHRX Comparison
Open Charts FSPHX vs HGHRXBanner chart's image
FSPHX vs HGHRX Comparison Chart in %
View a ticker or compare two or three
VS
FSPHX vs. HGHRX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FSPHX is a Hold and HGHRX is a StrongBuy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
FSPHX has more cash in the bank: 5.78B vs. HGHRX (723M). FSPHX pays higher dividends than HGHRX: FSPHX (0.45) vs HGHRX (0.00). FSPHX was incepted earlier than HGHRX: FSPHX (45 years) vs HGHRX (19 years). HGHRX (1.66) is less costly to investors than FSPHX (0.63). FSPHX is a more actively managed with annual turnover of: 69.00 vs. HGHRX (49.00). FSPHX (0) and HGHRX (0) have matching initial minimum investment requirements. HGHRX annual gain was more profitable for investors over the last year : 14.39 vs. FSPHX (-2.88). HGHRX return over 5 years is better than : -11.75 vs. FSPHX (-23.32).
FSPHXHGHRXFSPHX / HGHRX
Total Expense Ratio0.631.6638%
Annual Report Gross Expense Ratio0.631.6638%
Fund Existence45 years19 years-
Gain YTD-14.447-3.628398%
Front LoadN/AN/A-
Min. Initial Investment00-
Min. Initial Investment IRAN/AN/A-
Net Assets5.78B723M800%
Annual Yield % from dividends0.450.00-
Returns for 1 year-2.8814.39-20%
Returns for 3 years-14.195.15-276%
Returns for 5 years-23.32-11.75198%
Returns for 10 years24.7911.47216%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MIRTX34.50N/A
N/A
MFS Massachusetts Investors Tr R2
VCGAX37.34N/A
N/A
VALIC Company I Systematic Core Fund
VNVAX20.71N/A
N/A
Natixis Vaughan Nelson Mid Cap A
MSJAX20.42N/A
N/A
Morgan Stanley Global Endurance A
WOFRX67.12N/A
N/A
Allspring Opportunity R6